Caterpillar Bumps Up as Share Buyback Plan Offsets weak Earnings Report

Michael Teague |

Caterpillar Bumps Up as Share Buyback Plan Offsets weak Earnings ReportShares for machinery manufacturer Caterpillar (CAT) have risen to as much as $83 on Monday before pulling back slightly to a gain of 2.25 percent, or $82.23 per share, after the company announced the resumption of a $1 billion share buyback plan for the second quarter of 2013.



The company announced the plan as it reported earnings for the first quarter that fell significantly short of expectations. The world’s largest producer of mining equipment made profits of $880 million, or $0.31 per share on revenue of $13.2 billion, down from the prior-year period during which the company made $1.59 billion in profits, or $2.37 per share on revenue of $16 billion. Analyst estimates had earnings at $13.7 billion, or $1.38 per share.

Furthermore, for 2013 the company lowered its own forecast, cutting profit projections of $7 to $9 per share down to $7 per share, and sales from $60 to $68 billion down to $57 to $61 billion.

The much weaker earnings outlook is the result of a number of unfavorable global economic factors, most pressingly after the price of commodities, and especially metals, has taken huge losses over the last few weeks, and demand from China is lower as the country’s economy is set to grow slower than expected in 2013.

Caterpillar expects this year’s sales of mining equipment to take a 50 percent hit, especially for recent acquisitions such as China’s ERA Mining Machinery Ltd, which was purchased last year and has already seen a lag in production.

Still, company CFO Brad Halverson said, on the company’s website that while he sees the rest of 2013 as a challenge, he remains “very positive on the mining industry for the long term”.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer

Companies

Symbol Name Price Change % Volume
REGN Regeneron Pharmaceuticals Inc. 455.70 -2.54 -0.55 671,080 Trade
CAT Caterpillar Inc. 105.02 1.07 1.03 5,218,908 Trade

Comments

Emerging Growth

Immunovaccine Inc.

Immunovaccine Inc is clinical stage biopharmaceutical company. The Company develops products based on its proprietary vaccine enhancement platform in T cell activating therapies for cancer.

Private Markets

WayBetter

The spark hit Jamie when he saw co-workers competing to lose weight. Instead of pizzas and subs, they were eating salads and jogging along the river. Some were sneakily leaving…

Cross Campus

With over 500 members and operating 80,000 square feet by summer 2016, Cross Campus is one of the country’s top ten shared, collaborative office or "coworking" operators in the US.…